Medios AG (ILM1) AI Stock Analysis

• Market Cap: $312.70M
• Dividend Yield: N/A
• Average Volume (3M): 45.28K
• Price to Earnings (P/E): 16.6
• Beta (1Y): 0.80
• Revenue Growth: 9.27%
• EPS Growth: 65.65%
• Country: DE
• Employees: 472
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 0.29
• Shares Outstanding: 25,505,724
• 10 Day Avg. Volume: 55,289
• 30 Day Avg. Volume: 45,276
• PEG Ratio: -0.73
• Price to Book (P/B): 0.63
• Price to Sales (P/S): 0.17
• P/FCF Ratio: 4.80
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: 0.22
• Enterprise Value/Gross Profit: 2.25
• Enterprise Value/Ebitda: 5.23
• 1Y Price Target: $23.92
• Price Target Upside: 74.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: €16.50 ▲(20.61% Upside)

Medios AG's overall stock score is driven by strong financial performance and a stable technical outlook. The company's solid revenue growth and cash flow generation are significant strengths, while the valuation is reasonable. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates Medios AG's ability to expand its market presence and enhance its service offerings, supporting long-term business sustainability.

Cash Generation

Strong cash generation supports Medios AG's capacity to invest in growth opportunities and manage debt, ensuring financial stability and operational flexibility.

Capital Structure

A healthier capital structure with reduced leverage enhances Medios AG's financial resilience, allowing for better risk management and investment potential.

Negative Factors

Net Profit Margin

Low net profit margins may limit Medios AG's ability to reinvest in business growth and improve shareholder returns, impacting long-term profitability.

Return on Equity

Modest return on equity suggests Medios AG may not be fully optimizing its equity base, potentially affecting long-term growth and investor appeal.

Profitability

Limited profitability improvements may constrain Medios AG's capacity to enhance operational efficiency and competitiveness, affecting future performance.

Medios AG Business Overview & Revenue Model

Company Description

Medios AG (ILM1) is a leading healthcare company based in Germany, specializing in providing innovative solutions and services in the pharmaceutical and healthcare sectors. The company focuses on the distribution of specialty pharmaceuticals, as well as offering comprehensive care services to patients with chronic conditions. Medios AG aims to enhance patient outcomes through personalized healthcare solutions and has established a strong presence in the market by leveraging advanced technology and a robust logistics network.

How the Company Makes Money

Medios AG generates revenue primarily through the distribution of specialty pharmaceuticals, which includes high-cost medications for complex diseases. The company operates a business model that involves purchasing these pharmaceuticals from manufacturers at wholesale prices and then selling them to pharmacies and healthcare providers at a markup. Additionally, Medios AG offers value-added services such as patient management programs and digital health solutions, which further contribute to its revenue. Key partnerships with pharmaceutical companies and healthcare institutions enhance its market position and provide access to exclusive products, driving additional revenue streams. The integration of innovative technologies in their logistics and patient care processes also aids in reducing costs and improving efficiency, thereby positively impacting overall profitability.

Medios AG Financial Statement Overview

Summary

Medios AG exhibits a solid financial position with consistent revenue growth and improved operational efficiency. The balance sheet reflects a stable capital structure with moderate leverage. Cash flow performance is strong, with significant growth in free cash flow, enhancing financial flexibility. However, profitability remains a concern with low net profit margins, which could impact future growth potential.

Income Statement

Medios AG has shown consistent revenue growth with a TTM revenue growth rate of 2.93%. The gross profit margin is stable at around 8%, indicating efficient cost management. However, the net profit margin remains low at 0.78%, suggesting limited profitability. The EBIT and EBITDA margins have improved slightly, reflecting better operational efficiency.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.43, indicating a balanced approach to leveraging. Return on equity is relatively low at 2.93%, suggesting limited returns for shareholders. The equity ratio is strong, reflecting a solid capital structure with equity financing.

Cash Flow

Medios AG has demonstrated significant improvement in free cash flow growth, with a remarkable increase of 107.74% in the TTM period. The operating cash flow to net income ratio is 0.19, indicating adequate cash generation relative to net income. The free cash flow to net income ratio is robust at 0.81, highlighting strong cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.01B	1.88B	1.78B	1.61B	1.36B	626.54M
Gross Profit	194.33M	151.46M	108.63M	106.87M	68.48M	37.58M
EBITDA	83.52M	64.00M	52.82M	51.33M	34.68M	13.12M
Net Income	22.03M	12.55M	18.81M	18.33M	7.40M	5.53M
Balance Sheet
Total Assets	939.33M	934.36M	594.75M	575.96M	524.14M	194.54M
Cash, Cash Equivalents and Short-Term Investments	93.42M	106.00M	71.04M	79.21M	168.43M	19.79M
Total Debt	198.01M	238.37M	17.15M	17.63M	49.71M	19.23M
Total Liabilities	421.22M	424.17M	125.95M	127.91M	129.98M	52.11M
Stockholders Equity	518.11M	510.19M	468.81M	448.05M	394.16M	142.43M
Cash Flow
Free Cash Flow	91.28M	67.36M	15.14M	32.06M	48.70M	-42.98M
Operating Cash Flow	98.75M	73.67M	16.41M	37.12M	61.52M	-38.12M
Investing Cash Flow	-3.23M	-222.28M	-16.57M	-86.54M	17.36M	-5.88M
Financing Cash Flow	-69.53M	183.80M	-8.01M	-39.80M	69.76M	51.14M

Medios AG Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.68
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ILM1, the sentiment is Neutral. The current price of 13.68 is below the 20-day moving average (MA) of 14.30, above the 50-day MA of 13.63, and above the 200-day MA of 12.97, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 44.25 is Neutral, neither overbought nor oversold. The STOCH value of 11.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:ILM1.

Medios AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PSG	76 Outperform	€384.00M	19.73	52.68%	0.15%	15.20%	6.77%
M12	74 Outperform	€340.69M	19.08	15.61%	2.87%	6.52%	7.17%
ILM1	70 Outperform	$312.70M	16.61	4.18%	―	9.27%	65.65%
FYB	63 Neutral	€373.78M	-2.20	-34.48%	―	-14.84%	-338.52%
SBS	60 Neutral	€270.47M	16.88	―	2.73%	-1.64%	22.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HPHA	39 Underperform	€132.40M	-5.04	-112.95%	―	-64.15%	-39.31%

Medios AG Corporate Events

Medios AG Reports Strong Half-Year Financial Growth

Medios AG is a leading provider of Specialty Pharma Solutions in Europe, focusing on pharmaceutical supply, patient-specific therapies, and international business, with a strong emphasis on high-quality standards and innovative healthcare solutions.